Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.50 |
| ▸ | LAP3 | P28838 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
| ▸ | GRN | P28799 | 1/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7553789 | 1.00 | MAPT (0.53) | MAPTOPRD1ALDH1A1OPRM1OPRK1 | |
| SCHEMBL30661448 | 0.97 | OPRD1 (0.53) | MAPTOPRD1ALDH1A1OPRM1OPRK1 | |
| SCHEMBL30661446 | 0.97 | OPRD1 (0.53) | MAPTOPRD1ALDH1A1OPRM1OPRK1 | |
| SCHEMBL29414403 | 0.93 | MAPT (0.49) | MAPTOPRD1ALDH1A1OPRM1OPRK1 | |
| SCHEMBL29630425 | 0.91 | OPRD1 (0.55) | MAPTOPRD1ALDH1A1OPRM1OPRK1 | |
| SCHEMBL30285977 | 0.91 | OPRD1 (0.49) | MAPTOPRD1ALDH1A1OPRM1OPRK1 | |
| SCHEMBL29700057 | 0.91 | MME (0.54) | MAPTOPRD1ALDH1A1OPRM1OPRK1 | |
| SCHEMBL29815598 | 0.90 | PTGS1 (0.49) | MAPTOPRD1ALDH1A1OPRM1OPRK1 | |
| SCHEMBL29544382 | 0.90 | MME (0.44) | MAPTOPRD1ALDH1A1OPRM1OPRK1 | |
| SCHEMBL29590916 | 0.89 | ALDH1A1 (0.51) | MAPTOPRD1ALDH1A1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7225 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3701967-B1 | USE OF JACK BEAN LECTIN FOR INCREASING THE ABUNDANCE OF HEMATOPOIETIC STEM CELLS AND PROGENITOR CELLS IN BONE MARROW AND/OR EPIDERMAL STEM CELLS IN SKIN IN VIVO | THE SEC DEP OF ATOMIC ENERGY (IN) | 2025-07-30 | — | — | EP | claimed |
| WO-2025149851-A2 | METHODS FOR TREATING INFLAMMATORY DISEASES | YUYU PHARMA, INC. (KR) | 2025-07-17 | — | — | WO | claimed |
| EP-4371586-B1 | MULTIFUNCTIONAL CHITOSAN COMPOSITES FOR BONE DEFECT FILLING AND BONE TISSUE REGENERATION AND METHODS FOR OBTAINING THEM | SIEC BADAWCZA LUKASIEWICZ INSTYTUT CERAMIKI I MAT BUDOWLANYCH (PL) | 2025-04-16 | — | — | EP | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| WO-2022148418-A1 | PHARMACEUTICAL COMPOSITION CAPABLE OF BEING DELIVERED BY METERED DOSE INHALER | 江苏恒瑞医药股份有限公司 | 2022-07-14 | — | — | WO | claimed |
| CN-108290931-B | Novel polypeptides having affinity for PD-L1 | AFFIBODY AB (SE) | 2026-05-26 | — | — | CN | disclosed |
| CN-107513103-B | MASP isoforms as inhibitors of complement activation | OMEROS CORP. (US) | 2026-05-26 | — | — | CN | disclosed |
| CN-114080232-B | Extracellular vesicles for vaccine delivery | Lhasa Sales Co.,Ltd. (CH) | 2026-05-26 | — | — | CN | disclosed |
| CN-108350035-B | Cyclic polypeptides, methods for obtaining them and their use in therapy | 埃克斯欧力提斯药物公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-115433273-B | Anti-novel coronavirus rabbit recombinant monoclonal antibody with neutralization activity and application thereof | 苏州缔码生物科技有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-117285644-B | Phase change regulating element and application thereof | 清华大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-112752837-B | Natural killer cells | 帝国理工学院创新有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-113960313-A | Exosome ALK fusion protein magnetic immunochemiluminescence detection kit | 上海思路迪医学检验所有限公司 | 2022-01-21 | — | — | CN | disclosed |
| EP-1347783-A1 | CONJUGATES OF INTEGRIN RECEPTOR ANTAGONISTS AND A CYTOSTATIC AGENT HAVING SPECIFICALLY CLEAVABLE LINKING UNITS | Bayer Aktiengesellschaft (DE) | 2003-10-01 | — | — | EP | disclosed |
| US-20020183256-A1 | Cytostatic-integrin conjugates having specifically cleavable linking units | BAYER AKTIENGESELLSCHAFT (DE) | 2002-12-05 | — | — | US | disclosed |
| US-20020173452-A1 | Cytostatic-glycoconjugates having specifically cleavable linking units | BAYER AKTIENGESELLSCHAFT (DE) | 2002-11-21 | — | — | US | disclosed |
| WO-2002051444-A1 | CONJUGATES OF INTEGRIN RECEPTOR ANTAGONISTS AND A CYTOSTATIC AGENT HAVING SPECIFICALLY CLEAVABLE LINKING UNITS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-04 | — | — | WO | disclosed |
| WO-2002051862-A2 | CYTOSTATIC-GLYCOCONJUGATES HAVING SPECIFICALLY CLEAVABLE PEPTIDICLINKING UNITS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-04 | — | — | WO | disclosed |
| EP-1219634-A1 | Cytostatic-glycoconjugates having specifically cleavable peptidic linking units | Bayer Aktiengesellschaft (DE) | 2002-07-03 | — | — | EP | disclosed |
| EP-1219305-A1 | Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units | Bayer Aktiengesellschaft (DE) | 2002-07-03 | — | — | EP | disclosed |